18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether 18F-fluciclovine PET/CT of the brain, is
able to distinguish radiation necrosis from tumor progression in cases where MRI is
inconclusive.
18F-fluciclovine is an FDA approved radioactive diagnostic agent and is injected into the
participant and then taken up by cancer cells, which can then be visualized with a PET/CT
scan. 18F-fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is
still investigational for the purposes of this study.